Philip CHAN | Partner
陈嘉信
Capital Markets, Mergers & Acquisitions
  • Basic Information

    Philip is a partner in Haiwen Hong Kong office.  Philip has long been engaged in legal services including Hong Kong company law, listing rule, capital market transactions and cross-border mergers and acquisitions. Philip has extensive experience in Hong Kong capital market transactions and cross-border mergers and acquisitions. He has assisted clients in pre-IPO financing, listing, post-IPO compliance, control transfer, and privatization in various capital market transactions. In particular, he works on initial public offerings and post-listing mergers and acquisitions and compliance involving issuers in China (including H shares and red chips) and overseas backgrounds, as well as work related to the Hong Kong Stock Exchange's Listing Rules and the Securities and Futures Commission's Takeovers and Mergers Code.

  • Professional History

    Philip has accumulated more than 16 years of experience in leading companies and law firms, and was awarded the honor of "40 Under 40" by LexisNexis, a well-known legal institute LexisNexis in 2022. Prior to joining Haiwen, Philip was the General Counsel of a Hong Kong-listed company with market capitalisation of over HK$10 billion, responsible for the company's legal matters and advising on the legal aspects of compliance, investigation, investment/divestment transactions. Previously, Philip was a Senior Legal Counsel of a Fortune 500 company and a Consultant at Clifford Chance in Shanghai and Hong Kong for more than 10 years, where he accumulated extensive experience in the industry.

  • Experience Highlights

    Philip's recent experience includes advising: 

      the transfer of the controlling stake of HKICIM Group and the triggering of a Mandatory General Offer under the Takeovers and Mergers Code;

      a family fund invested in Terminus (an AI business company) as a private equity investor;

      CDB International Investment Limited sold a 29.99% stake in China New Town, a Hong Kong-listed real estate company (obtaining confirmation from the Securities and Futures Commission that it would not trigger a Mandatory General Offer under the Takeovers and Mergers Code);

      China Mobile's investment in a Hong Kong-listed software company, which may trigger Hong Kong's Takeovers Code obligations to provide advice and represent it in negotiations with the Hong Kong Securities and Futures Commission;

      Clarity Medical on its listing and global offering in Hong Kong;

      Genor Biopharma (holding company of Hillhouse Capital) on its listing and global offering in Hong Kong;

      Morgan Stanley Private Equity in the listing and global offering of its wholly-owned investee company Home Control on the Hong Kong Stock Exchange;

      Morgan Stanley Private Equity obtained an overseas M&A loan and acquired equity in a domestic company;

      ChemChina: Advising on the restructuring of Syngenta Group, ChemChina and Sinochem Corporation and the acquisition of a controlling stake in Hong Kong-listed Sinochem Hong Kong Holdings Limited;

      various transactions with Blackstone, Henderson Land, Wheelock Property and other prominent counterparties for aggregated consideration of over US$3 billion; regulators’ queries, compliance to applicable laws and rules, various financing and refinancing transactions, etc;

      HNA Foods: advising on its proposed acquisition of a Hong Kong-listed food company and making a general offer;

      HNA Investment: Advising on its proposed acquisition of a controlling stake in a Hong Kong-listed financial sector company through a voluntary partial tender offer;

      China Mobile's investment in a Hong Kong-listed H-share company;

      Hong Kong International Construction Investment (687.hk) invested in Hong Kong Airlines;

      the sponsors in the spin off and Hong Kong listing of BOCOM International Holdings Company Limited;

      VPower, a Hong Kong-based international power solutions company on its listing and global offering in Hong Kong;

      China Resources Pharmaceutical on its listing and global offering in Hong Kong;

      China Huarong's investment in MI Energy, an energy company, was restructured;

      a transaction in which an affiliate of China Travel Service International increased its capital in China National Tourism Administration;

      major transaction in which China General Nuclear Power Co., Ltd. acquired the assets of China General Nuclear Power Group for approximately RMB10 billion;

      well-known companies such as China National Offshore Oil Corporation, COFCO, Beijing Enterprises Holdings, KKR, CICC Capital, Sequoia Capital, and China Life Fund for analysis and transactions under Hong Kong law;

      BAML and UBS in the approximately US$1.2 billion global offering and Hong Kong listing of Everbright Securities;

      CICC, BAML and ABCI in the Hong Kong listing and global offering of CGN Power Co., Ltd. of approximately US$3 billion. CGN Power is the first and only nuclear power operator listed on the Hong Kong Stock Exchange;

      BOCI, CCBI and ABCI in the approximately US$1 billion global offering and Hong Kong listing of Bank of Tianjin;

      the sponsors in the approximately US$8 billion global offering and Hong Kong listing of China Postal Savings Bank;

      Morgan Stanley in the approximately US$200 million IPO and listing of PW Medtech Limited, a leading medical device company in China, on the Main Board of the Hong Kong Stock Exchange;

      Morgan Stanley, UBS, J.P. Morgan, BOCI, CITIC in the approximately US$1.36 billion IPO and listing of Huishang Bank Corporation Limited, the largest city commercial bank in Anhui, China, on the Main Board of the Hong Kong Stock Exchange;

      J.P. Morgan, Morgan Stanley and UBS, as underwriters, on the US$1.9 billion Hong Kong listing and Rule 144A global offering of Wynn Macau Limited, owner and operator of casinos and resorts;

      the underwriters in the Hong Kong listing and global offering plan of an online gaming company in PRC with VIE structure;

      J.P. Morgan on the listing of a mining subsidiary of Wuhan Iron and Steel (Group) Corporation;

      Goldman Sachs and Morgan Stanley, as underwriters, on the US$450 million red-chip listing and Rule 144A global offering of Yingde Gases Group Company, a leading industrial gas supplier in China;

      Kunlun Energy in respect of its very substantial acquisition of Petrochina Kunlun Gas for over US$2.3 billion;

      on the top-up placing of Hong Kong-listed companies such as Sino Biopharmaceutical Limited, China Agri-Industries Holdings Limited, and Kunlun Energy, Real Gold Mining Limited;

      New World Development on its potential large scale acquisition of a Grade-A property in Hong Kong;

      Singamas on its application for whitewash exemption under the Takeovers Code from the Securities and Futures Commission of Hong Kong in connection with the rights issue;

      NWS Holdings Limited in its pre-IPO investment in an infrastructure technology solutions company;

      GIC Private Ltd in respect of its interests in China International Capital Corporation Limited;

      China Construction Bank in its acquisition of AIG Finance (Hong Kong) Limited.

  • Education

    Philip received his Bachelor's degree in Business Administration (Law) and Bachelor's degree in Laws from University of Hong Kong. He is a qualified solicitor of Hong Kong SAR and England & Wales. Philip has also passed the lawyer examination in Guangdong-Hong Kong-Macao Greater Bay Area, China.

  • Language

    Chinese (Cantonese, Mandarin), English.

News

Contact Us
Address:20/F Fortune Financial Center 5 Dong San Huan Central Road Chaoyang District Beijing 100020, China
Telephone:+86 10 8560 6888
Fax:+86 10 8560 6999
Mail:haiwenbj@haiwen-law.com
Address:Unit 2605,Jing An Kerry Center Tower 1 No.1515 Nan Jing West Road Jing'an District Shanghai 200040, China
Telephone:+86 21 6043 5000
Fax:+86 21 5298 5030
Mail:haiwensh@haiwen-law.com
Address:Suites 1101-1104, 11/F, One Exchange Square, 8 Connaught Place, Central, Hong Kong, China
Telephone:+852 3952 2222
Fax:+852 3952 2211
Mail:haiwenhk@haiwen-law.com
Address:Room 3801, Tower Three, Kerry Plaza 1 Zhong Xin Si Road, Futian District, Shenzhen 518048, China
Telephone:+86 755 8323 6000
Fax:+86 755 8323 0187
Mail:haiwensz@haiwen-law.com
Address:Unit 01, 10-12, 20/F, China Overseas International Center Block C, 233 Jiao Zi Avenue, High-tech District, Chengdu 610041, China
Telephone:+86 28 6391 8500
Fax:+86 28 6391 8397
Mail:haiwencd@haiwen-law.com
Address:Room 3508-3509, 35/F, Hainan Building 5 Guoxing Avenue, Meilan District Haikou 570100, China
Telephone:+86 898 6536 9667
Fax:+86 898 6536 9667
Mail:haiwenhn@haiwen-law.com

Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258

关于提示公众注意的声明

海问律师事务所近期收到反映,有不法分子冒充本所律师,推销投资产品。该行为涉嫌诈骗,且严重损害了本所声

誉,本所对此表示高度重视,并特此向公众声明。

×